MarketPulse

targeted protein degradation

6 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Kymera Therapeutics Advances IBD Pipeline With Promising KT-579 Preclinical Data

Kymera Therapeutics showcases KT-579 preclinical data matching approved IBD therapies ahead of Phase 1 trials in late 2026.
KYMRclinical trialinflammatory bowel disease
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Kymera Therapeutics Lands $45M Milestone as FDA Fast-Tracks Asthma Drug

Kymera Therapeutics receives $45M from Gilead option exercise and FDA Fast Track designation for asthma drug KT-621, with Phase 2b data expected late 2027.
GILDKYMRasthmaGilead Sciences
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Nurix Therapeutics Showcases Protein Degradation Pipeline Potential at AACR 2026

Nurix Therapeutics unveils preclinical data showing protein degradation pipeline effectiveness, with NRX-0305 achieving 142% lifespan extension in melanoma models.
PFESNYGILDNRIXdrug developmentoncology pipeline
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Prelude Therapeutics' KAT6A Degrader Shows Complete Tumor Regressions in Breast Cancer Models

Prelude Therapeutics shows complete tumor regressions with PRT13722, a first-in-class oral KAT6A degrader, planning IND filing mid-2026 and clinical trials by year-end.
PRLDprecision oncologyHR+/HER2- breast cancer
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Nurix Therapeutics Posts $87.2M Loss While Advancing Bexobrutideg Clinical Pipeline

Nurix Therapeutics reported Q1 2026 revenue of $6.3M (down 66% YoY) and $87.2M net loss, maintaining $540.7M cash while advancing bexobrutideg clinical program.
SNYGILDNRIXclinical trialsimmunology
GlobeNewswire Inc.GlobeNewswire Inc.··Amphista Therapeutics

Amphista Therapeutics Names New Leadership to Advance AMX-883 Toward IND Filing

Amphista Therapeutics appoints new CEO and CMO ahead of planned AMX-883 IND application in April 2026 for acute myeloid leukemia treatment.
LLYNVSclinical developmentIND application